Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

Scientists discover key component to repair the molecular motor of human heart

A team of scientists from Loyola University Chicago's Stritch School of Medicine have discovered a critical component for renewing the heart's molecular motor, which breaks down in heart failure.

20 May 2021

A study reports the first case of an upper extremity deep vein thrombosis (DVT) recurrence due to COVID-19 infection

Researchers have reported the first case of COVID-19 triggering a rare occurrence of potentially severe blood clots forming in the arms.

19 May 2021

Type of heart failure may influence which approach is optimal for patients with AFib

Among patients with both heart failure and atrial fibrillation (AFib), treatment strategies focused on controlling the heart rhythm (using catheter ablation) and those focused on controlling the heart rate (using drugs and/or a pacemaker) showed no significant differences in terms of death from any cause or progression of heart failure.

18 May 2021

Sotagliflozin reduces adverse cardiovascular events across patients with diabetes, heart failure

Patients with both diabetes and heart failure who were treated with sotagliflozin, a novel investigational drug for diabetes, for a median of nine to 16 months experienced reductions of 22% to 43% in the risk of death or worsening heart failure compared with similar patients who were treated with a placebo

18 May 2021

Pirfenidone significantly reduces a marker of heart muscle scarring

Patients with heart failure with preserved ejection fraction who took the antifibrotic drug pirfenidone saw a significant reduction in a marker of heart muscle scarring compared with patients who received a placebo, based on findings from an early-phase trial presented at the American College of Cardiology's 70th Annual Scientific Session.

18 May 2021

Omecamtiv mecarbil significantly reduces hospitalizations among patients with severe heart failure

The experimental heart failure drug omecamtiv mecarbil reduced heart failure hospitalizations by a greater margin among patients with more severely reduced ejection fraction, a measure indicating severe impairment in the heart's pumping ability, compared with those who had moderately reduced ejection fraction, according to research presented at the American College of Cardiology's 70th Annual Scientific Session.

18 May 2021

New cardiac rehabilitation intervention improves quality of life in hospitalized heart failure patients

An innovative cardiac rehabilitation intervention started earlier and more custom-tailored to the individual improved physical function, frailty, quality-of-life, and depression in hospitalized heart failure patients, compared to traditional rehabilitation programs.

17 May 2021

Study raises more concerns about the use of combined EPA/DHA through supplements

Doctors often recommend Omega-3s to help patients lower their cholesterol and improve heart health. Those Omega-3s can come from fatty fish like salmon and mackerel, or supplements that often contain a combination of the acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).

17 May 2021

Study: Novel rehabilitation program improves outcomes in older heart-failure patients

Heart failure (HF) - when the heart can't pump enough blood and oxygen through the body - affects approximately 6.2 million adults in the United States and is the primary cause of hospitalization in the elderly. Unfortunately, older adults with heart failure often have poor outcomes resulting in reduced quality of life, high mortality and frequent rehospitalizations.

17 May 2021

Frequent blood testing protocol for heart attack did not improve patient outcomes after one year

Using more sensitive and frequent repeat testing of a blood test that indicates heart injury to guide the treatment of low-risk patients with symptoms of a possible heart attack resulted in patients being discharged earlier and receiving fewer cardiac stress tests but did not improve patient outcomes after one year, according to research presented at the American College of Cardiology's 70th Annual Scientific Session.

17 May 2021

Older heart failure patients significantly benefit from tailored cardiac rehab program

Older patients hospitalized with acute heart failure who participated in a novel 12-week physical rehabilitation (rehab) program tailored to address their specific physical impairments had significant gains not only in physical functioning but also quality of life and depression compared with those receiving usual care, regardless of their heart's ejection fraction, according to a new study presented at the American College of Cardiology's 70th Annual Scientific Session.

17 May 2021

Sacubitril/valsartan drug did not significantly reduce cardiovascular death after heart attack

The heart failure drug sacubitril/valsartan did not significantly reduce the rate of heart failure or cardiovascular death following a heart attack compared to ramipril, an angiotensin-converting enzyme (ACE) inhibitor proven effective in improving survival following heart attacks.

17 May 2021

Farxiga approved in the US for the treatment of chronic kidney disease in patients at risk of progression with and without type-2 diabetes

Approval is the most significant advancement in the treatment of chronic kidney disease in more than 20 years. In DAPA-CKD Phase III trial, Farxiga demonstrated unprecedented reduction in the risk of the composite of worsening of renal function, end-stage kidney disease and cardiovascular or renal death.

From AstraZeneca 14 May 2021

Blocking fat-busting enzyme with a drug compromises cardiac repair during acute heart failure

Blocking the fat-busting enzyme lipoxygenase with a synthetic inhibitor throws the immune system's innate inflammatory response out of whack, compromising cardiac repair during acute heart failure, USF Health researchers found.

10 May 2021

Point-of-care ultrasonography can improve the correctness of diagnosis in patients with acute dyspnea

Point-of-Care UltraSonography (POCUS) deployed during the emergency treatment of patients with acute dyspnea has enormous advantages over standard diagnostic pathways.

10 May 2021

$Hospitalized COVID-19 patients with impaired first-phase ejection fraction have higher death risk$

Hospitalized COVID-19 patients with impaired first-phase ejection fraction have higher death risk

Hospitalized COVID-19 patients with impaired first-phase ejection fraction were nearly 5 times more likely to die compared to patients with healthier measures of this early, often undetected sign of heart failure, according to new research published today in Hypertension, an American Heart Association journal.

10 May 2021

Global spread of COVID-19 has raised serious concern for patients with transthyretin amyloidosis

The global spread of COVID-19 has raised serious concern for patients with chronic disease. A correlation has been identified between the severity of COVID-19 and a patient's preexisting comorbidities.

7 May 2021

Mental health may influence a person's recovery after heart attack

Young and middle-aged adults who reported severe psychological distress--such as depression or anxiety--after suffering a heart attack were more than twice as likely to suffer a second cardiac event within five years compared with those experiencing only mild distress, according to a study presented at the American College of Cardiology's 70th Annual Scientific Session.

6 May 2021

New service enables patients to recover safely at home, avoid hospitalization

A new service piloted at Penn Medicine allowed a proportion of patients to avoid hospitalization by providing them with greater support after visiting the emergency department.

5 May 2021

New genetic mutation increases risk for atrial fibrillation, heart failure in Black people

A new mutation found in a gene associated with an increased risk of atrial fibrillation poses a significantly increased risk for heart failure in Black people.

5 May 2021

Heart Failure News and Research

Further Reading

Scientists discover key component to repair the molecular motor of human heart

A study reports the first case of an upper extremity deep vein thrombosis (DVT) recurrence due to COVID-19 infection

Type of heart failure may influence which approach is optimal for patients with AFib

Sotagliflozin reduces adverse cardiovascular events across patients with diabetes, heart failure

Pirfenidone significantly reduces a marker of heart muscle scarring

Omecamtiv mecarbil significantly reduces hospitalizations among patients with severe heart failure

New cardiac rehabilitation intervention improves quality of life in hospitalized heart failure patients

Study raises more concerns about the use of combined EPA/DHA through supplements

Study: Novel rehabilitation program improves outcomes in older heart-failure patients

Frequent blood testing protocol for heart attack did not improve patient outcomes after one year

Older heart failure patients significantly benefit from tailored cardiac rehab program

Sacubitril/valsartan drug did not significantly reduce cardiovascular death after heart attack

Farxiga approved in the US for the treatment of chronic kidney disease in patients at risk of progression with and without type-2 diabetes

Blocking fat-busting enzyme with a drug compromises cardiac repair during acute heart failure

Point-of-care ultrasonography can improve the correctness of diagnosis in patients with acute dyspnea

Hospitalized COVID-19 patients with impaired first-phase ejection fraction have higher death risk

Global spread of COVID-19 has raised serious concern for patients with transthyretin amyloidosis

Mental health may influence a person's recovery after heart attack

New service enables patients to recover safely at home, avoid hospitalization

New genetic mutation increases risk for atrial fibrillation, heart failure in Black people

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News